CompletedNot Applicable

Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

United States20,143 participantsStarted 2023-06-19

Plain-language summary

The purpose of this study is to assess a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of cardiac amyloidosis (CA).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Mayo Clinic cardiology or hematology providers who care for adult patients * Mayo Clinic providers who consent to participate on this study Exclusion Criteria: \- None

What they're measuring

To determine if AI ECG algorithm and enhanced algorithms and education enable earlier diagnosis of cardiac amyloidosis

Timeframe: 1 year

Trial details

NCT IDNCT05557162

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-23

View on ClinicalTrials.gov More Cardiac Amyloidosis trials